Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2020 pubmed 11 citations

Cationic amphipathic peptide analogs of cathelicidin LL-37 as a probe in the development of antimicrobial/anticancer agents.

Tzitzilis. Athanasios A; Boura-Theodorou. Anastasia A; Michail. Vassilios V; Papadopoulos. Stylianos S; Krikorian. Dimitrios D; Lekka. Marilena E ME; Koukkou. Anna-Irini AI; Sakarellos-Daitsiotis. Maria M; Panou-Pomonis. Eugenia E

Key Findings

  • Replacing the N‑terminal charge and swapping lysine for leucine created a peptide (Ac‑FKRIVQRILD‑FLR‑NH2) that killed A549 cancer cells at 3.9 µg/mL with no red‑cell damage
  • Adding IIKK or LLKKL motifs to the 17‑29 segment gave peptides that inhibited gram‑negative bacteria (MIC 3‑7.5 µg/mL) and also killed cancer cells (IC50 9.8‑12.9 µg/mL) without hemolysis
  • Circular dichroism confirmed that the active analogs adopt a helical structure, indicating that proper shape is important for activity

Practical Outcomes

  • For DIY biohackers, these modified LL‑37 fragments provide a blueprint for designing peptides that target cancer cells or microbes while sparing human cells, but they are still early‑stage lab findings. Synthesizing and testing them requires peptide chemistry skills and thorough safety validation before any real‑world use.

Summary

Researchers tweaked a short piece of the human immune peptide LL‑37 and found some versions can kill lung cancer cells or bacteria in lab dishes without hurting red blood cells. The changes that worked involved swapping certain building blocks and adding short motifs called IIKK or LLKKL, which helped the peptide keep its helical shape and become more selective.

Abstract

Cathelicidin LL-37 belongs to the class of human defense peptides and is overexpressed in many cancers. Segments of LL-37 derived through biochemical processes have a wide range of activities. In this study, novel analogs of the 13-amino acid cathelicidin 17-29 amide segment F<sup>17</sup> KRIV<sup>21</sup> QR<sup>23</sup> IK<sup>25</sup> DF<sup>27</sup> LR-NH<sub>2</sub> were prepared and examined for their antimicrobial and hemolytic activities, as well as for their cytotoxicity on cancer bronchial epithelial cells. Selected substitutions were performed on residues R<sup>23</sup> and K<sup>25</sup> in the hydrophilic side, V<sup>21</sup> and F<sup>27</sup> in the hydrophobic side of the interphase, and F<sup>17</sup> that interacts with cell membranes. Specific motifs IIKK and LLKKL with anticancer and antimicrobial activities isolated from animals were also inserted into the 17-29 fragment to investigate how they affect activity. Substitution of the amino-terminal positive charge by acetylation and replacement of lysine by the aliphatic leucine in the peptide analog Ac-FKRIVQRIL<sup>25</sup> DFLR-NH<sub>2</sub> resulted in significant cytotoxicity against A549 cancer cells with an IC<sub>50</sub> value 3.90 &#x3bc;g/mL, with no cytotoxicity to human erythrocytes. The peptide Ac-FKRIVQI<sup>23</sup> IKK<sup>26</sup> FLR-NH<sub>2</sub> , which incorporates the IIKK motif and the peptides FKRIVQL<sup>23</sup> L<sup>24</sup> KK<sup>26</sup> L<sup>27</sup> LR-NH<sub>2</sub> and Ac-FKRIVQL<sup>23</sup> L<sup>24</sup> KK<sup>26</sup> L<sup>27</sup> LR-NH<sub>2</sub> , which incorporate the LLKKL motif, displayed potent antimicrobial activity against gram-negative bacteria (MIC 3-7.5 &#x3bc;g/mL) and substantial cytotoxicity against bronchial epithelial cancer cells, (IC<sub>50</sub> 12.9-9.8 &#x3bc;g/mL), with no cytotoxic activity for human erythrocytes. The helical conformation of the synthetic peptides was confirmed by circular dichroism. Our study shows that appropriate substitutions, mainly in positions of the interphase, as well as the insertion of the motifs IIKK and LLKKL in the cathelicidin 17-29 segment, may lead to the preparation of effective biological compounds.

Study Information

Provider

pubmed

Year

2020

Date

2020-06-21T00:00:00.000Z

DOI

10.1002/psc.3254

Citations

11

References

51